S-1/A: Actuate Therapeutics Files Amendment for IPO, Citing Positive Interim Trial Data

Actuate Therapeutics amends its S-1 filing, highlighting promising interim results from its Phase 2 trial of elraglusib in metastatic pancreatic cancer and plans for upcoming clinical trials.

Summary

• Actuate Therapeutics has filed an amendment to its S-1 registration statement for an initial public offering.
• The company is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers through GSK-3 inhibition.
• Their lead drug candidate, elraglusib, is being evaluated in a Phase 2 trial for metastatic pancreatic cancer (mPDAC).
• Interim data from the Phase 2 trial (Actuate-1801 Part 3B) shows a median overall survival (mOS) of 12.2 months in the elraglusib combination therapy arm versus 7.3 months in the control group (HR=0.60; log-rank p=0.012).
• The company plans to initiate a Phase 1 dose escalation study for Elraglusib Oral Tablet in patients with advanced, refractory solid cancers.
• They also intend to initiate a Phase 2 study in refractory metastatic melanoma.
• The company has granted the underwriters an option to purchase up to an additional 833,333 shares of common stock.
• Top line results from the ongoing mPDAC trial are expected in the first quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. The positive interim clinical trial results and plans for further development are encouraging. However, the company's financial situation and dependence on a single product candidate introduce significant risks.

Positives

• Promising interim data from the Phase 2 mPDAC trial suggests a potential survival benefit with elraglusib.
• The company is expanding its pipeline with plans for oral tablet formulation studies and additional Phase 2 trials.
• Elraglusib has received Fast Track and Orphan Drug Designations from the FDA for pancreatic cancer.
• The mPDAC trial completed enrollment four months faster than predicted.

Negatives

• The company has a limited operating history and has incurred significant operating losses since inception.
• Their financial condition raises substantial doubt about their ability to continue as a going concern.
• The current Phase 2 study design cannot be used to support accelerated approval.
• The company depends entirely on the success of elraglusib, which is their only product candidate.

Risks

• The interim data is preliminary and subject to change upon completion of the full data analysis.
• The company may not be able to obtain regulatory approval for elraglusib or any future product candidates.
• Clinical trials may be delayed or fail.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company will require substantial additional capital to finance its operations.
• The company's drug substance manufacturer is in China, which could pose supply chain risks.

Future Outlook

The company intends to develop elraglusib in a broad list of advanced cancer indications, initially in patients with refractory disease and with an initial focus on metastatic pancreatic cancer. The company believes that the net proceeds from this offering, together with its existing cash and cash equivalents, will be sufficient to fund its operations for at least the next 18 months.

Management Comments

• Management believes that the ability to extend survival by even a few months would be considered meaningful in the mPDAC patient population.
• Management expects that top line data will then be available in the first quarter of 2025 based on enrollment of the last patients in the study in February 2024.

Industry Context

The document highlights the significant unmet need in pancreatic cancer treatment, noting the low survival rates and the limitations of existing therapies. It positions elraglusib as a potential new treatment option, particularly in combination with existing chemotherapy regimens.

Comparison to Industry Standards

• The mOS of 7.7 months in Part 1 benchmarks favorably with mOS 8-10 months for other active single agents evaluated in Phase 1.
• The elraglusib mOS of 11.9 months for the ITT compares favorably with the mOS of 11.2 months for FOLFIRINOX, the other first line regimen used for patients with mPDAC or more recently with irinotecan liposomal injection (Onivyde) (mOS=11.1 months).
• The mOS of 12.2 months in the elraglusib combination therapy arm versus 7.3 months in the GnP control group arm (HR=0.60; log-rank p=0.012) compares favorably with the recently approved irinotecan liposomal injection and would complement the other first line regimens currently used to treat mPDAC and provide a basis for approval for use in patients with mPDAC that had not previously received systemic treatment for their metastatic disease.

Related Party Transactions

• The document mentions related party transactions, including convertible promissory notes issued to Bios Clinical Opportunity Fund, LP, a fund affiliated with two members of the board of directors of the Company and a majority shareholder.

Stakeholder Impact

• Shareholders: Potential for increased value if elraglusib is successful, but also risk of dilution from future capital raises.
• Employees: Potential for job growth and career advancement if the company is successful.
• Patients: Potential for new treatment options for difficult-to-treat cancers.
• Creditors: Repayment of debt is dependent on the company's financial success.

Next Steps

• Complete the ongoing Elraglusib Injection Phase 2 mPDAC trial (Actuate-1801 Part 3B).
• Complete the existing pediatric refractory cancer Phase 1 dose escalation trial and initiate and complete the Phase 2 portion of this study in patients with refractory Ewing sarcoma (Actuate-1902).
• Finalize development plans and initiate and complete a Phase 1 dose escalation study for the Elraglusib Oral Tablet in patients with advanced, refractory solid cancer.
• Finalize development plans and initiate and enroll patients in a Phase 2 study in refractory metastatic melanoma (Actuate-2401).
• Initiate further conversations with the FDA to discuss possible registration if the future mOS data is positive in favor of the elraglusib/GnP combination.
• Plan the Phase 3 mPDAC trial and finalize development plans for an additional randomized Phase 2 trial in patients with metastatic refractory colorectal cancer.

Key Dates

Keywords

elraglusib, pancreatic cancer, metastatic, GSK-3, clinical trial, Actuate Therapeutics, Phase 2, Ewing sarcoma, FDA, oncology, mPDAC, IPO